BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30925751)

  • 21. Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis.
    Ahmad S; Ahmed A
    Endothelium; 2005; 12(1-2):89-95. PubMed ID: 16036320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium.
    Kaza E; Ablasser K; Poutias D; Griffiths ER; Saad FA; Hofstaetter JG; del Nido PJ; Friehs I
    Cardiovasc Res; 2011 Feb; 89(2):410-8. PubMed ID: 20935166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor (VEGF) and its receptors.
    Neufeld G; Cohen T; Gengrinovitch S; Poltorak Z
    FASEB J; 1999 Jan; 13(1):9-22. PubMed ID: 9872925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy.
    Mabeta P; Steenkamp V
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential gene expression of vascular endothelial growth factor isoforms and their receptors in the development of the rat masseter muscle.
    Ishii H; Oota I; Arakawa T; Takuma T
    Arch Oral Biol; 2002 Jul; 47(7):505-10. PubMed ID: 12208074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
    Lohela M; Bry M; Tammela T; Alitalo K
    Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer.
    Zygalaki E; Tsaroucha EG; Kaklamanis L; Lianidou ES
    Clin Chem; 2007 Aug; 53(8):1433-9. PubMed ID: 17599955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anti-angiogenic isoforms of VEGF in health and disease.
    Qiu Y; Hoareau-Aveilla C; Oltean S; Harper SJ; Bates DO
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1207-13. PubMed ID: 19909248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage.
    Pufe T; Petersen W; Tillmann B; Mentlein R
    Arthritis Rheum; 2001 May; 44(5):1082-8. PubMed ID: 11352239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.
    Hulse RP; Drake RA; Bates DO; Donaldson LF
    Neurobiol Dis; 2016 Dec; 96():186-200. PubMed ID: 27616424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
    Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis.
    Gu F; Li X; Kong J; Pan B; Sun M; Zheng L; Yao Y
    Biochem Biophys Res Commun; 2013 Nov; 441(1):18-24. PubMed ID: 24125722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm.
    Ladomery MR; Harper SJ; Bates DO
    Cancer Lett; 2007 May; 249(2):133-42. PubMed ID: 17027147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils.
    de Paulis A; Prevete N; Fiorentino I; Rossi FW; Staibano S; Montuori N; Ragno P; Longobardi A; Liccardo B; Genovese A; Ribatti D; Walls AF; Marone G
    J Immunol; 2006 Nov; 177(10):7322-31. PubMed ID: 17082651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
    Meyer M; Clauss M; Lepple-Wienhues A; Waltenberger J; Augustin HG; Ziche M; Lanz C; Büttner M; Rziha HJ; Dehio C
    EMBO J; 1999 Jan; 18(2):363-74. PubMed ID: 9889193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
    Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
    Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity.
    Kawamura H; Li X; Harper SJ; Bates DO; Claesson-Welsh L
    Cancer Res; 2008 Jun; 68(12):4683-92. PubMed ID: 18559514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.